ArticleTranslational lung cancer research2022

Durvalumab plus novel agents in non-small cell lung cancer-a new COAST on the horizon?

Wolfram C M Dempke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.